Many of our doctors are constantly vigilant about our developing skeletal related issues. Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of [...]
In clinical trials Enzalutamide (Xtandi) significantly increased the overall survival and radiographic progression-free survival of men when compared with placebo. The trial, called PREVAIL evaluated men who were asymptomatic and minimally symptomatic, chemotherapy-naive with metastatic castration-resistant prostate cancer. The researchers expanded the data analysis and evaluated the effect of Xtandi on the men’s health-related quality [...]
Most people don't know the many advances that the Department of Defense Congressionally Directed Medical Research Program (DOD PCRP) has brought to the PROSTATE CANCER COMMUNITY. Did you know that the program is directly responsible for funding the initial development of three of the very new drugs we have available? The DOD PCRP is directly [...]
Analysis of the PREVAIL Trial showed that Enzalutamide (Xtandi) significantly increased overall survival and radiographic progression-free survival compared with placebo in men with prostate cancer who were asymptomatic and minimally symptomatic, chemotherapy-naive and who had metastatic castration-resistant prostate cancer (mCRPC). Now, an additional analysis of the data has shown the effect enzalutamide also has on [...]
At the current AUA Annual Meeting going on in New Orleans, there was a presentation given by Haitao Zhang and colleagues. They described their work developing a novel blood-based assay (test) for detecting androgen receptor (AR) splice variants in men with advanced prostate cancer. Their work relies on the premise that AR-V7 expression underlies resistance [...]